Glatiramer Acetate Complexes CpG Oligodeoxynucleotides into Nanoparticles and Boosts Their TLR9-Driven Immunity

Area of Science:

• Immunology
• Nanotechnology
• Cancer Therapy

Background:

• Unmethylated cytosine-guanine oligodeoxynucleotides (CpG ODNs) activate Toll-like receptor 9 (TLR9), showing antitumor potential but facing clinical limitations due to toxicity.
• Glatiramer acetate (GA), a lysine-rich polypeptide, can complex with CpG ODNs to form nanoparticles, potentially improving localized delivery and reducing systemic side effects.

Purpose of the Study:

• To evaluate the physiochemical properties and immunological signaling of GA complexed with different classes (A, B, and C) of CpG ODNs.
• To assess the impact of GA complexation on CpG ODN cellular uptake, endolysosomal trafficking, and subsequent immune responses in vitro and in vivo.
• To determine if GA-CpG nanoparticles can enhance antitumor efficacy while mitigating systemic immune-related toxicities.

Main Methods:

• Physiochemical characterization of GA-CpG nanoparticles (classes A, B, C).
• Assessment of cellular uptake and endolysosomal trafficking of GA-CpG nanoparticles.
• In vitro and in vivo immunological assays to evaluate immune responses and antitumor effects.
• Comparison of GA-CpG nanoparticles against uncomplexed CpG ODNs.

Main Results:

• GA successfully formed cationic spherical nanoparticles with all CpG ODN subtypes, preserving their immunological activity.
• GA complexation enhanced cellular uptake of CpG ODNs and increased their retention in early endosomes.
• GA-CpG nanoparticles amplified immunological responses and demonstrated potent tumor suppression in vivo.
• Systemic immune-related toxicities were significantly mitigated compared to systemic CpG ODN administration.

Conclusions:

• Glatiramer acetate serves as an effective nucleic acid delivery scaffold for CpG ODNs.
• GA-CpG nanoparticles improve the efficacy and safety profile of CpG adjuvants for cancer immunotherapy.
• This approach holds promise for advancing CpG ODN-based cancer treatments.